CHGA Monoclonal Antibody

1. Elevated serum CGA was negatively associated with overall survival in men with metastatic castrate resistant prostate cancer. Serum CGA represents a prognostic biomarker that may complement circulating tumor cells enumeration. PMID:29858590
2. Patients with higher catestatin levels developed worse ventricular function during the follow-up period. Single-point catestatin was effective to predict LVEDD change. And concurrently increasing catestatin and NT-proBNP levels predicted the highest risk of LV remodeling. This study suggests an important prognostic information of catestatin on LV remodeling. PMID:28397784
3. CgA and NSE are clinically valuable tumor markers in neuroblastoma and they merit prospective clinical evaluations as such. PMID:29737901
4. Vasostatin-1 is stably overexpressed in serum of patients with ileal and pancreatic neuroendocrine neoplasms. PMID:29723285
5. Results suggest that severe atopic dermatitis is associated with higher stress levels. Simple salivary CgA measurements may be useful as an objective assessment of patient stress. PMID:28406540
6. cardiac atria express but do not secrete CgA into circulation in patients with atrial disease PMID:28685598
7. These results suggest that circulating full-length CgA is an important inhibitor of angiogenesis and tumor growth, and that cleavage of its C-terminal region markedly reduces its activity. Pathophysiological changes in CgA blood levels and/or its fragmentation might regulate disease progression in cancer patients. PMID:27683038
8. Results show that chronic lymphocytic leukemia (CLL) patients had increased plasma levels of chromogranin A (CgA), compared to normal subjects, particularly those >70-year-old or those treated with proton pump inhibitors. PMID:27203389
9. The authors show that CHGA-415 T/C polymorphism is an independent risk factor of poor prognosis in critically ill patients PMID:28254729
10. Concurrent increases in plasma BNP (B-type natriuretic peptide) and CST levels predicted the highest risk for both all-cause and cardiac deaths in chronic heart failure patients. PMID:27771336
11. Full-length CgA is an independent indicator of atherosclerotic plaques in carotid artery stenosis. PMID:28190616
12. Even a single baseline measurement of CgA can be useful in establishing prognosis in this group, if this parameter exceeds its upper normal limit more than tenfold. PMID:28095720
13. Compared with chromogranin A, chromogranin B may be more useful during proton pump inhibitor treatment and can detect tumors without liver metastases. PMID:28334992
14. Salivary impairments and high levels of CHGA are associated with T2DM patients. In addition, CGHA polymorphisms might be associated with salivary gland hypofunction and higher salivary CHGA production in T2DM patients. This could be a significant insight to establish a role for salivary CHGA as a potential clinical biomarker to T2DM. PMID:26750135
15. we could provide evidence that established stress-related biomarkers ET-1, MCP-1, CGA were differentially regulated among patients with AF compared to healthy controls. PMID:28886122
16. Combined plasma CgA concentrations and World Health Organization grading may assist in better stratification of PNET patients in terms of the risk of recurrence. PMID:28043759
17. Metastatic castration-resistant prostate cancer patients with an early high CGA rise may demonstrate a subgroup with poor outcome due to underlying small cell/neuroendocrine cell transformation. PMID:28870943
18. genetic association studies in population in India: Data suggest that common polymorphisms (SNPs) in CHGA promoter are associated with cardiometabolic disorders; c-Rel has a role in activating CHGA promoter haplotype 2 (variant T alleles at -1018 and -57 bp) under basal and pathophysiological conditions. (CHGA = chromogranin A; c-Rel = c-Rel proto-oncogene protein) PMID:28667172
19. Multivariate analyses of nonfunctional pancreatic neuroendocrine tumor patients with both grade and CgA recorded found poorly differentiated tumors and very high CgA negatively impacted survival. PMID:28501118
20. High chromogranin A expression is associated with neuroendocrine differentiation in colorectal cancer. PMID:28351413
21. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. PMID:27324226
22. Plasma catestatin was associated with coronary collateral developments, suggesting a useful biomarker for coronary collateral development and potential target for therapeutic angiogenesis in patients with coronary artery chronic total occlusions (CTO). PMID:27304618
23. Increased myocardial CgA glycosylation and impaired CgA processing to catestatin in heart failure be considered detrimental because CST reduces diastolic Ca2+ leak via direct CaMKIIdelta inhibition. PMID:28209766
24. Data suggest pancreastatin, a 49 residue post-translational fragment of chromogranin A, as a routinely tested biomarker in neuroendocrine tumors (NETs) and in particular small bowel NET. PMID:26684860
25. Data indicate that measurement of chromogranin A (CgA) alone is sufficient in the management of patients with neuroendocrine tumours (NETs) and that routine additional measurement of chromogranin B (CgB) provides little added value. PMID:26608723
26. Data show that chrysin suppressed cell proliferation and reducing expression of achaete-scute complex-like 1 (ASCL1) and the neuroendocrine biomarker chromogranin A (CgA). PMID:26403073
27. In a Japanese population, the Ser-364 allele was associated with elevated systolic blood pressure and pulse pressure, consistent with increased arterial stiffness. PMID:26211667
28. ChrA levels were not effective in predicting outcomes or detecting recurrences of Merkel cell carcinoma. PMID:26299616
29. Decreased CSF levels of chromogranin A were found in Parkinson disease patients with orthostatic hypotension. PMID:26359267
30. In both mice and men the Gly364Ser polymorphism conferred metabolic traits such as elevated HDL and lowered norepinephrine levels; it was associated with superior baroreflex function and therefore better response to stress. PMID:26556564
31. In patients with resected pancreatic neuroendocrine tumors, an elevated preoperative CgA level was negatively associated with disease-free survival and overall survival. PMID:26850182
32. In astrocytes from multiple sclerosis white matter lesions the expression of chromogranin A is increased. PMID:26683597
33. Receiver operating characteristic analyses showed that ChgA autoantibodies are valuable in the predictive diagnosis of non-small cell lung cancer (NSCLC), suggesting that serum autoantibodies to ChgA-derived peptides are promising novel markers of NSCLC PMID:26186986
34. Diagnostic value of circulating chromogranin a for neuroendocrine tumors PMID:25894842
35. Data indicate that ADP-ribosylation factor 1 (Arf1) colocalizes with chromogranin A and regulates secretion of insulin like growth factor 1 (IGF-1) and is required for anchorage dependent growth. PMID:25754106
36. catestatin plays an important role in the progress of acute myocardial infarction PMID:25848973
37. The CHGA 3'-UTR C+87T disrupts an miR-107 motif, with differential effects on CHGA expression, and a cis:trans (mRNA:miR) interaction regulates the association of CHGA with BP and hypertensive nephropathy. PMID:25392232
38. Chromogranin A measurements are significantly assay-dependent and caution should be applied in the interpretation of CgA measurement for assessment of neuroendocrine tumor status. PMID:25532001
39. Chromogranin A (10-19) and chromogranin A (43-52) were identified as antigens for autoreactive CD8(+) T cells in Type 1 diabetes patients. PMID:25958206
40. Vasoconstriction-Inhibiting Factor (VIF), a degradation product of chromogranin A, is a vasoregulatory peptide that modulates the vasoconstrictive effects of angiotensin II by acting on the angiotensin II type 2 receptor. PMID:25810338
41. Patients with irritable bowel syndrome present a low density of CgA compared with controls. PMID:25174455
42. Report QT/heart rate variability in a genomically "humanized" chromogranin a monogenic mouse model with hyperadrenergic hypertension. PMID:24821335
43. Report fast and reliable measurement of chromogranin A with automated KRYPTOR assay. PMID:25651748
44. The study shows that chromogranin A is a useful marker for diagnosing pancreatic neuroendocrine tumors (pNET) in Japanese populations and for distinguishing patients with pNET from patients with other pancreatic diseases. PMID:25220535
45. reliable pathologic and circulating maker for diagnosis of gastroenteropancreatic neuroendocrine neoplasm PMID:25501094
46. a model to explain how the chromogranin A/Catecholamine complex governs the accumulation and exocytosis of secreted amines PMID:25077558
47. High serum Chromogranin A levels are associated with low response to chemotherapy in metastatic castration-resistant prostate cancer. PMID:24741024
48. Elevated plasma catestatin levels are predictive of malignant arrhythmia in patients with acute myocardial infarction. PMID:24631953
49. Letter: report diagnostic role of chromogranin A immunohistochemistry in hyalinizing trabecular tumor of the thyroid. PMID:25012947
50. High serum Chromogranin A levels are associated with pancreatic neuroendocrine tumors. PMID:25099181

Show More

Hide All